The Tumor Necrosis Factor Ligand Superfamily Member 13 pipeline drugs market research report outlays comprehensive information on the Tumor Necrosis Factor Ligand Superfamily Member 13 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tumor Necrosis Factor Ligand Superfamily Member 13 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Genito Urinary System, Immunology, Hematological Disorders, and Central Nervous System which include the indications IgA Nephropathy (Berger’s Disease), Membranous Glomerulonephritis, Systemic Lupus Erythematosus, Myasthenia Gravis, Antiphospholipid Syndrome, Acquired (Autoimmune) Hemolytic Anemia, Multiple Sclerosis, and Unspecified Neurologic Disorders. It also reviews key players involved in Tumor Necrosis Factor Ligand Superfamily Member 13 targeted therapeutics development with respective active and dormant or discontinued products.
The Tumor Necrosis Factor Ligand Superfamily Member 13 pipeline targets constitutes close to eight molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, and Preclinical stages are 1, 3, 1, 1, and 1 respectively. Similarly, the universities portfolio in Phase II comprises 1 molecule.
Tumor Necrosis Factor Ligand Superfamily Member 13 overview
Tumor necrosis factor superfamily member 13 (TNFSF13). This is also known as a proliferation inducing ligand (APRIL) and is secreted from antigen-presenting cells. TNFSF13 binds to TNFRSF17/BCMA, a member of the TNF receptor family and plays a role in the regulation of tumor cell growth. Also, it is engaged in adaptive and innate immune responses by binding to receptors on B and T cells.
For a complete picture of Tumor Necrosis Factor Ligand Superfamily Member 13’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
